Figure 4 from The Use of TF-Ag-α to Selectively Capture Tumor-Derived Extracellular Vesicles and Enhance the Predictive Performance of Extracellular Vesicle PD-L1 for Response to Immune Checkpoint Inhibitors
Evaluation of TEX TF-Ag-α and TEXTF-Ag-α PD-L1 for predicting anti–PD-1 therapy response in a validation cohort of patients with NSCLC (25 responders and 37 nonresponders). TEX TF-Ag-α and TEXTF-Ag-α PD-L1 expression at pretreatment baseline (A and B), at the end of the first treatment cycle (E and F), and their FCs (I–L). ROC analysis of their predictive performance at baseline (C and D), at the end of the first treatment cycle (G and H), and FCs (M and N). Kaplan–Meier survival analysis showed that patients with TEXTF-Ag-α PD-L1 FC >1.59 had substantially longer PFS (O) and OS (P) compared with patients with TEXTF-Ag-α PD-L1 FC ≤1.59 (P < 0.001). *, P < 0.05; **, P < 0.01; ****, P < 0.0001. NS, not statistically significant. A.U., arbitrary unit.